A detailed history of American International Group, Inc. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 20,020 shares of FDMT stock, worth $420,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,020
Previous 19,862 0.8%
Holding current value
$420,219
Previous $402,000 58.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$17.03 - $35.87 $2,690 - $5,667
158 Added 0.8%
20,020 $637,000
Q4 2023

Feb 13, 2024

BUY
$9.76 - $21.25 $2,928 - $6,375
300 Added 1.53%
19,862 $402,000
Q3 2023

Nov 13, 2023

BUY
$12.64 - $19.76 $55,123 - $86,173
4,361 Added 28.69%
19,562 $249,000
Q2 2023

Aug 04, 2023

BUY
$15.16 - $23.26 $10,884 - $16,700
718 Added 4.96%
15,201 $274,000
Q1 2023

May 12, 2023

BUY
$15.45 - $23.19 $4,434 - $6,655
287 Added 2.02%
14,483 $248,000
Q4 2022

Feb 10, 2023

SELL
$6.85 - $25.46 $349 - $1,298
-51 Reduced 0.36%
14,196 $315,000
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $1,405 - $2,318
202 Added 1.44%
14,247 $115,000
Q2 2022

Aug 12, 2022

BUY
$5.68 - $15.99 $1,011 - $2,846
178 Added 1.28%
14,045 $98,000
Q1 2022

May 13, 2022

SELL
$13.16 - $22.64 $12,831 - $22,074
-975 Reduced 6.57%
13,867 $210,000
Q4 2021

Feb 11, 2022

BUY
$19.56 - $32.94 $65,995 - $111,139
3,374 Added 29.42%
14,842 $326,000
Q3 2021

Nov 12, 2021

BUY
$22.73 - $36.04 $135,561 - $214,942
5,964 Added 108.36%
11,468 $309,000
Q2 2021

Aug 13, 2021

BUY
$22.2 - $42.29 $21,511 - $40,979
969 Added 21.37%
5,504 $133,000
Q1 2021

May 07, 2021

BUY
$35.94 - $52.67 $162,987 - $238,858
4,535 New
4,535 $197,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $680M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.